Background Severe left ventricular (LV) systolic dysfunction is an uncommon complication of hypertrophic cardiomyopathy (HCM) that is associated with poor prognosis. Small observational series suggest that patients with rare causes of HCM are more likely to develop systolic impairment than those with idiopathic disease or mutations in cardiac sarcomeric protein genes. The aim of this study was to test this hypothesis by comparing the prevalence of systolic dysfunction and its impact on prognosis in patients with different causes of HCM.
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ABSTRACT
Background Severe left ventricular (LV) systolic dysfunction is an uncommon complication of hypertrophic cardiomyopathy (HCM) that is associated with poor prognosis. Small observational series suggest that patients with rare causes of HCM are more likely to develop systolic impairment than those with idiopathic disease or mutations in cardiac sarcomeric protein genes. The aim of this study was to test this hypothesis by comparing the prevalence of systolic dysfunction and its impact on prognosis in patients with different causes of HCM.
Methods and results 1697 patients (52 (40-63) years, 1160 (68%) males) with HCM followed at two European referral centres were studied. Diagnosis of specific aetiologies was made on the basis of clinical examination, cardiac imaging and targeted genetic and biochemical testing. The primary survival outcome was all-cause mortality or heart transplantation (HTx) for endstage heart failure (HF). Secondary outcomes were HFrelated death, sudden cardiac death, stroke-related death and non-cardiovascular death. Systolic dysfunction (LV ejection fraction <50% by two-dimensional (2D) echocardiography) at first evaluation was more frequent in rare phenocopies than in idiopathic or sarcomeric HCM (105/409 (26%) vs 40/1288 (3%), respectively ( p<0.0001)). All-cause death/HTx and HF-related death were more frequent in rare phenocopies compared with idiopathic or sarcomeric HCM ( p<0.0001). All-cause mortality and HF-related death were highest in patients with cardiac amyloidosis ( p<0.0001). Conclusions In adults with HCM, LV systolic dysfunction is more frequent in those with rare phenocopies. When combined with age at presentation, it is a marker for specific aetiologies and is associated with poorer long-term survival.
Hypertrophic cardiomyopathy (HCM) is a common cardiac disease caused by a number of genetic and acquired disorders. 1 Mutations in genes coding for cardiac sarcomeric proteins account for the majority of cases, but other diseases including inherited disorders of metabolism, myocardial infiltration, neuromuscular disorders and malformation syndromes can present with a similar phenotype. In many cases, obvious clinical features suggest the diagnosis of these less common disorders, but in some patients they may be overlooked or misdiagnosed if the index of clinical suspicion is low.
Severe left ventricular (LV) systolic dysfunction, commonly referred to as end-stage disease or the 'burnt-out phase', is an uncommon but important evolution of idiopathic or sarcomeric HCM. [2] [3] [4] [5] In tertiary referral centres, end-stage disease has a prevalence of 2-5% and an incidence of 0.5-1 cases per 100 patient-years and is associated with a poor prognosis due to high rates of refractory heart failure (HF) and sudden arrhythmic death.
3-7 Small observational series suggest that patients with some of the rarer HCM phenocopies are more likely to develop systolic impairment than those with disease caused by sarcomeric protein gene mutations [8] [9] [10] [11] [12] and current European Society of Cardiology (ESC) guidelines suggest that LV systolic dysfunction is one of several clinical features that assist in the differential diagnosis of HCM. 13 The aim of this study was to test this hypothesis by comparing the prevalence of systolic dysfunction in patients with different causes of HCM. A secondary aim was to assess the impact of aetiology on long-term survival.
METHODS

Study design and setting
This was a retrospective, longitudinal cohort study involving patients from two European cardiomyopathy centres-The Heart Hospital, University College Hospitals Trust, London, UK, and Bologna University Hospital, Italy. The study conformed to the principles of the Helsinki declaration.
Study population and patient assessment
Patients were identified by systematically searching hospital records and clinical databases. Patients were evaluated using medical history, pedigree analysis, physical examination, ECG, cardiac imaging and laboratory testing. Further specialised tests such as skeletal muscle and endomyocardial biopsy, and molecular genetic testing were performed when there were features from the pedigree analysis, clinical examination or preliminary investigations that suggested a possible rare phenocopy.
All patients included in the study were ≥16 years of age. HCM was defined as a maximal LV wall thickness (MWT) ≥15 mm or ≥13 mm in patients with unequivocal familial disease 14 and/or a diagnosed rare non-sarcomeric phenocopy.
The Heart Hospital population comprised a cohort of unrelated consecutive patients with idiopathic or sarcomeric HCM who were tested for sarcomeric protein gene mutations using high-throughput sequencing between 2011 and 2013 15 The cohort from Bologna University Hospital comprised consecutive patients with idiopathic or sarcomeric HCM (some of whom have been included in other recently published studies) [16] [17] [18] [19] and with the same phenocopies as described above assessed between 1980 and 2013.
Data collection
Data were collected independently at each participating centre using uniform methodology. Clinical characteristics were assessed at first (baseline) evaluation. LV systolic dysfunction was defined as a resting LV ejection fraction (LVEF) <50% measured using two-dimensional echocardiography and the biplane Simpson method. 5 
Study outcomes
The primary outcome was all-cause mortality or heart transplantation (HTx) for end-stage HF. Secondary outcomes were as follows: sudden cardiac death, HF-related death, stroke-related death and non-cardiovascular (CV) death. When the cause of death was not known, the death was considered non-cardiac in all analyses. 20 The cause of death was ascertained at each centre using hospital and primary healthcare records, death certificates, postmortem reports and interviews with witnesses.
Sudden cardiac death was defined as natural death due to cardiac causes, occurring within 1 hour of the onset of acute symptoms. Death was also classified as sudden if it occurred unexpectedly but was unwitnessed, such as in bed overnight. Appropriate implantable cardioverter-defibrillator intervention for ventricular fibrillation or ventricular tachycardia and aborted cardiac death with successful cardiac resuscitation were considered as equivalent to sudden cardiac death. HF-related death included deaths in individuals with symptoms of progressive HF including cardiogenic shock. 20 
Statistical analysis
Data are reported as median and IQR for continuous variables or frequencies ( percentage) for categorical variables.
Comparison of clinical and laboratory variables between patient subgroups was performed with two-sample t-test for continuous parametric variables and Mann-Whitney U test for all continuous non-parametric variables. Categorical variables were compared using χ 2 test for parametric data. Comparisons of multiple groups of continuous non-parametric data were performed using the Kruskal-Wallis test.
The follow-up time for each patient was calculated from the date of their first evaluation at each centre to the date of the primary end point or to the date of their most recent clinical evaluation. The cumulative probability for the occurrence of an outcome was estimated using the Kaplan-Meier method and log-rank test from the first clinical evaluation at the referral centre.
All p values were two-sided and the results were considered statistically significant if <0.05. SPSS (V.22.0) was used for all statistical analyses.
RESULTS
The combined study population consisted of 1703 patients. Six patients were excluded as there were no verifiable data on LV systolic function. Eighty-seven per cent of the entire cohort had a wall thickness ≥15 mm. Of the remainder, 7% had a family history of HCM caused by a sarcomeric protein gene mutation and 6% had rare phenocopies; 74% (304/409) of the phenocopies had MWT ≥15 mm. Figure 1 shows the patient population selection process, and table 1 summarises the different aetiological subgroups at each centre.
Clinical characteristics at first evaluation
Demographic and clinical features of patients at first evaluation are described in table 2. Patients with rare phenocopies were more often diagnosed because of one or more non-cardiac symptoms (140 (35%) vs 0 (0%), p<0.0001) and were more symptomatic at first evaluation (New York Heart Association (NYHA) functional class III-IV 97 (24%) vs 144 (11%), p=0.013) than patients with idiopathic HCM or HCM caused by sarcomeric protein gene mutations.
Prevalence of LV systolic impairment
Systolic impairment was present in 145 patients (9%). The prevalence of systolic impairment was higher in patients with rare phenocopies compared with patients with idiopathic or sarcomeric HCM (table 2) .
The prevalence of LV systolic dysfunction among patients with rare phenocopies was highest in patients with AL amyloidosis (40%, 46/115 patients) followed by SSA (38%, 18/48 patients), GSD (31%, 5/16 patients, 3 with PRKAG2 mutation), hereditary transthyretin type (TTR) amyloidosis (28%, 24/86 patients), Friedreich's ataxia (18%, 2/11 patients), mitochondrial disease (13%, 3/23 patients) and AFD (8%, 7/85 patients). None of the patients with a diagnosis of Noonan syndrome, LEOPARD syndrome, FHL1 or CPT II deficiency showed LV systolic impairment at first evaluation. In the overall population, one patient with idiopathic HCM had undergone septal myectomy and no patient had a previous alcohol septal ablation.
Age at first evaluation according to aetiology Idiopathic or sarcomeric HCM was the most frequent diagnosis at all ages. Other disorders were distributed across all decades with a higher prevalence for syndromic and metabolic diseases in the young and cardiac amyloidosis in older age groups. Median age at first evaluation was lowest in patients with Friedreich's ataxia (20 (17-23) 
Prognosis in relation to aetiology and LV systolic function
Median duration of follow-up from first evaluation was 3.7 (IQR 1.6-7.2) years. In the overall population, 58 patients were assessed only at first evaluation and therefore were excluded from the outcome analysis. In total, 250 (15%) patients died or underwent orthotopic HTx. Death from any cause and HTx were more frequent in rare phenocopies compared with idiopathic or sarcomeric HCM (129 (33%) vs 121 (10%), respectively, p<0.0001) (figure 4A). Similar results were found for HF-related death (34 (9%) vs 21 (2%), respectively, p<0.0001) (figure 4B). All-cause mortality, CV death, death from HF and HTx were all more common in (49) 462 (27) Phenocopies, n (%) 409 (24) 161 (9) 248 (15) AL amyloidosis, n (%)
115 (7) 6 (0.4) 109 (6) Hereditary TTR amyloidosis, n (%)
86 (5) 6 (0.4) 80 (5) AFD, n (%) 85 (5) 77 (5) patients with rare phenocopies compared with patients with idiopathic or sarcomeric HCM or non-syndromic HCM (table 3) . In total, 13 (9%) of the 145 patients with systolic impairment underwent HTx. Kaplan-Meier analysis demonstrated that allcause mortality/HTx and HF-related mortality were highest in patients affected by cardiac amyloidosis ( figure 5A, B) . HF-related deaths only occurred in patients with cardiac amyloidosis (n=21), idiopathic or sarcomeric HCM (n=21) and AFD (n=4). All-cause death/HTx and death from HF were more frequent in patients with LV systolic dysfunction than in patients with preserved LV systolic function ( p<0.0001). No gender differences were present for any analyses.
DISCUSSION
To the best of our knowledge, this is the first study to assess the prevalence of LV systolic dysfunction in adult patients with HCM caused by different aetiologies. The recent ESC guidelines suggest that LV systolic impairment should be considered as diagnostic 'red flag' for less common causes of otherwise unexplained LV hypertrophy. 1 Our study confirmed this hypothesis, showing that LV systolic dysfunction is more frequent in rarer phenocopies compared with idiopathic or sarcomeric HCM. Moreover, the prevalence of different phenocopies is age dependent.
Relation between aetiology and age at presentation
The starting point in this study was a clinical diagnosis of HCM based on LV wall thickness.
1 While HCM is most commonly an inherited disease caused by mutations in genes encoding sarcomeric proteins, approximately 5-10% of patients have rarer disorders that may be overlooked unless they are specifically excluded. In the most recent ESC guideline on HCM, 1 great emphasis is placed on the search for diagnostic clues or 'red flags' that point towards one of these phenocopies. This study shows that one of the most important of these diagnostic pointers is the age at presentation as many phenocopies manifest predominantly in early, middle or late decades of life. In some instances, presentation is confined to particular age ranges; for example, wild-type TTR amyloidosis in the elderly and Friedreich's ataxia in the young.
Systolic function in relation to aetiology
In most patients with idiopathic or sarcomeric HCM, LV systolic function measured using EF is within or above normal ranges due to a small LV cavity and preserved radial function, but several studies have shown that some patients develop progressive systolic impairment during follow-up. The prevalence of severe systolic impairment (arbitrarily defined as an EF of <50%) using conventional echocardiographic criteria ranges from 2% to nearly 5%, with an annual incidence of <1%. [3] [4] [5] This so-called end-stage disease can develop at any age, but in the majority of patients, the time from onset of symptoms to diagnosis of severe systolic impairment is about 10-15 years. 3 The development of severe systolic HF is associated with a poor prognosis, with rapid progression to death or transplantation and a mortality of up to 11% per year. 5 In this study, the prevalence of severe LV systolic impairment was nine times higher in patients with rare phenocopies compared with patients with idiopathic or sarcomeric HCM. Just as with the aetiology of HCM, the clinical profile of patients with systolic impairment varied with age in that Friedreich's ataxia and GSD showed the earliest presentation with systolic impairment compared with patients with mitochondrial disease, AFD and wild-type amyloidosis in whom systolic impairment was a late event. None of the patients with a diagnosis of Noonan syndrome, LEOPARD syndrome, FHL1 mutations or CPT II deficiency showed LV systolic impairment at first evaluation.
Figure 4
Outcomes in patients with idiopathic or sarcomeric hypertrophic cardiomyopathy (HCM) versus those with rare phenocopies. Cumulative incidence of all-cause mortality or heart transplantation (HTx) (A) and heart failure (HF)-related death (B) in idiopathic or sarcomeric HCM versus phenocopies. Number at risk at each time point displayed on the x-axis. 33 (2) 18 (1) 15 (4) 0.006 SD, n (%) 60 (4) 41 (3) 19 (5) <0.0001 Stroke-related death, n (%)
11 (1) 9 (1) 2 (0.5) Non-CV death, n (%)
46 (3) 26 (2) 20 (5) Unknown, n (%)
50 (3) 6 (0.5) 44 (11) CV, cardiovascular; HF, heart failure; HTx, heart transplantation; SD, sudden death.
Impact of systolic dysfunction on prognosis
During follow-up, the rate of death and HTx was three times higher in patients with rare phenocopies than in patients with idiopathic or sarcomeric HCM due to a much higher incidence of death from progressive HF. This finding was driven predominantly by patients with AL-related and TTR-related amyloidosis who had the poorest survival among all the patient subgroups, a finding consistent with the known natural history of these diseases. [21] [22] [23] The overall rate of HTx was low in the total study cohort, but was performed in almost 10% of patients with systolic impairment at first evaluation, highlighting the need for close monitoring of this cohort.
Clinical implications
The term hypertrophic cardiomyopathy embraces a wide range of conditions with different natural histories and prognosis. This study shows that the presence of severe systolic impairment should prompt a systematic search for rare phenocopies informed by the age of the patient at first presentation. The implications for individual patients vary according to the underlying disease, but in some cases disease-specific therapies that impact on morbidity and prognosis are available. In patients without rare phenocopies, regular monitoring for symptomatic deterioration and progressive HF should be performed.
CONCLUSION
In an adult population of patient with HCM, LV systolic dysfunction is more frequent in rare causes of HCM. When combined with age at presentation, it is a marker for specific aetiologies and is associated with poorer long-term survival. Figure 5 Outcomes in idiopathic or sarcomeric hypertrophic cardiomyopathy (HCM) compared with specific rare phenocopies. Cumulative incidence of all-cause mortality or heart transplantation (HTx) (A) and heart failure (HF)-related death (B) according to specific aetiologies. Number at risk at each time point displayed on the x-axis. AFD, Anderson-Fabry disease; AL, immunoglobulin light chain; SSA, senile systemic amyloidosis; TTR, transthyretin type.
Key messages
What is already known on this subject? Hypertrophic cardiomyopathy (HCM) is a generic term that encompasses a number of different diseases. Left ventricular (LV) systolic dysfunction is an uncommon complication of the disease, but its relation to underlying aetiology has not been investigated. Similarly, there are no studies in the literature investigating the impact of aetiology on long-term prognosis in large populations of patients with HCM.
What might this study add?
This study shows that LV systolic dysfunction at first evaluation is more frequent in rare HCM phenocopies than in disease caused by mutations in cardiac sarcomeric protein gene (the most common cause of HCM). The causes of systolic LV dysfunction varied with age in that there was a higher prevalence of syndromic and metabolic diseases in the young, whereas cardiac amyloidosis was exclusively seen in older age groups. The underlying aetiology also influenced survival with rare phenocopies-in particular cardiac amyloidosis-being associated with a poor long-term survival.
How might this impact on clinical practice?
These findings show that systolic LV dysfunction in patients with HCM is a diagnostic clue that should prompt a systematic search for rarer phenocopies informed by the age of the patient at first presentation. These rare conditions are important because they have prognostic implications and can be overlooked or misdiagnosed if the index of clinical suspicion is low.
LIMITATIONS
The aim of our study was not to explore the prevalence of the different diseases underlying the hypertrophic phenotype, but rather to explore the clinical relevance of LV systolic dysfunction in different HCM phenocopies.
The population in this study is heterogeneous in relation to genetic analysis (the UK population being represented by patients consecutively investigated by next-generation sequencing while in the Italian population classic genetic analysis by Sanger was performed on a case-by-case basis). Therefore, no statistical analysis on the impact of genotype has been performed.
Data collection in the two participating centres took place over very different time periods and could have affected outcomes due to changes in treatment regimens, particularly for patients with amyloidosis.
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